nach oben

International Journal of Hematology

Erschienen in:

01.08.2015 | Original Article

The impact of JAK2V617F mutation on different types of thrombosis risk in patients with essential thrombocythemia: a meta-analysis

verfasst von: Youwen Qin, Xiaorui Wang, Chuxian Zhao, Chun Wang, Yining Yang

Erschienen in: International Journal of Hematology | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

To assess the effect of JAK2V617F on different thrombotic risks in essential thrombocythemia (ET) patients, we identified eligible studies from several databases including Pubmed, Embase, and Cochrane Central Register of Controlled Trials (up to November 2014). Twenty-two studies of 2922 ET patients were included in exploring the relationship between JAK2V617F and the risk of thrombosis. Compared to JAK2V617F-negative ET patients, JAK2V617F-positive ET patients had higher odd risks (ORs) of arterial thrombosis [OR = 2.59 (1.84–3.65)] and venous thrombosis [OR = 2.10 (1.53–2.88)]. The JAK2V617F-positive group was also more prone to increased risk of microcirculatory disturbances [OR = 1.50 (0.97–2.32)]. Moreover, JAK2V617F may indicate increased risk of either arterial [OR = 1.71 (1.22–2.39)] or venous thrombosis [OR = 2.90 (1.54–5.46)] before diagnosis of ET. During follow-up, JAK2V617F might not be related to arterial thrombosis [OR = 1.90 (0.90–2.08)], but rather venous thrombosis [OR = 1.95 (1.08–3.53)]. In conclusion, JAK2V617F increased the risk of arterial and venous thrombosis in ET patients, while understanding its role in microcirculatory disturbances will require further studies.

Nur mit Berechtigung zugänglich

Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Cancer Genome Project: acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054–61.PubMedCrossRef

Hsiao HH, Yang MY, Liu YC, Lee CP, Yang WC, Liu TC, et al. The association of JAK2V617F mutation and leukocytosis with thrombotic events in essential thrombocythemia. Exp Hematol. 2007;35:1704–7.PubMedCrossRef

Lee HS, Park LC, Lee EM, Lee SJ, Shin SH, Im H, et al. Incidence rates and risk factors for vascular events in patients with essential thrombocythemia: a multicenter study from Korea. Clin Lymphoma Myeloma Leuk. 2012;12:70–5.PubMedCrossRef

Cetin G, Ozkan T, Turgut S, Ali CM, Cem AM, Ayer M, et al. Evaluation of clinical and laboratory findings with JAK2 V617F mutation as an independent variable in essential thrombocytosis. Mol Biol Rep. 2014;41:6737–42.PubMedCrossRef

Rudzki Z, Sacha T, Stoj A, Czekalska S, Wojcik M, Skotnicki AB, et al. The gain-of-function JAK2 V617F mutation shifts the phenotype of essential thrombocythemia and chronic idiopathic myelofibrosis to more “erythremic” and less “thrombocythemic”: a molecular, histologic, and clinical study. Int J Hematol. 2007;86:130–6.PubMedCrossRef

Alvarez-Larran A, Cervantes F, Bellosillo B, Giralt M, Julia A, Hernandez-Boluda JC, et al. Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Leukemia. 2007;21:1218–23.PubMedCrossRef

Speletas M, Katodritou E, Daiou C, Mandala E, Papadakis E, Kioumi A, et al. Correlations of JAK2-V617F mutation with clinical and laboratory findings in patients with myeloproliferative disorders. Leuk Res. 2007;31:1053–62.PubMedCrossRef

Zhang S, Qiu H, Fischer BS, Li W, Duan L, Sun X, et al. JAK2V617F patients with essential thrombocythemia present with clinical features of polycythemia vera. Leuk Lymphoma. 2008;49:696–9.PubMedCrossRef

Palandri F, Ottaviani E, Salmi F, Salmi F, Catani L, Polverelli N, et al. JAK2V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients. Leuk Lymphoma. 2009;50:247–53.PubMedCrossRef

10.

Ziakas PD. Effect of JAK2V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain. Haematologica. 2008;93:1412–4.PubMedCrossRef

11.

Dahabreh IJ, Zoi K, Giannouli S, Zoi C, Loukopoulos D, Voulgarelis M. Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia. Leuk Res. 2009;33:67–73.PubMedCrossRef

12.

Lussana F, Caberlon S, Pagani C, Kamphuisen PW, Büller HR, Cattaneo M. Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review. Thromb Res. 2009;124:409–17.PubMedCrossRef

13.

Murphy S, Peterson P, Iland H, Laszlo J. Experience of the polycythemia vera study group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol. 1997;34:29–39.PubMed

14.

Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292–302.PubMedCrossRef

15.

Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22:14–22.PubMedCrossRef

16.

Falanga A, Marchetti M. Thrombotic disease in the myeloproliferative neoplasms. Hematology/the Education Program of the American Society of Hematology. Am Soc Hematol Educ Program. 2012;2012:571–81.

17.

Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of non randomised studies in meta-analyses (2015). http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.

18.

Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed

19.

Mantel N. Chi-square tests with one degree of freedom: extensions of the Mantel–Haenszel procedure. J Am Stat Assoc. 1963;58:690–700.

20.

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRef

21.

Higgins JPT, Green S. Chapter 9: analysing data and undertaking meta-analyses. Cochrane hand book for systematic reviews of interventions version 5.1.0. 2011.

22.

Tobias A. Assessing the influence of a single study in the meta-analysis estimate. Stata Techn Bull. 1999;8:15–7.

23.

Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.PubMedCrossRef

24.

Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCentralPubMedCrossRef

25.

Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol. 2008;61:991–6.PubMedCrossRef

26.

Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455–63.PubMedCrossRef

27.

Palmer TM, Peters JL, Sutton AJ, et al. Contour-enhanced funnel plots for meta-analysis. Stata J. 2008;8:242–54.

28.

Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005;366:1945–53.PubMedCrossRef

29.

Cheung B, Radia D, Pantelidis P, Yadegarfar G, Harrison C. The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia. Br J Haematol. 2006;132:244–5.PubMedCrossRef

30.

Finazzi G, Rambaldi A, Guerini V, Carobbo A, Barbui T. Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. Haematologica. 2007;92:135–6.PubMedCrossRef

31.

Antonioli E, Guglielmelli P, Poli G, Bogani C, Pancrazzi A, Longo G, et al. Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica. 2008;93:41–8.PubMedCrossRef

32.

Larsen TS, Pallisgaard N, Moller MB, Hasselbalch HC. High prevalence of arterial thrombosis in JAK2 mutated essential thrombocythaemia: independence of the V617F allele burden. Hematology. 2008;13:71–6.PubMedCrossRef

33.

Moreno MJ, Lozano ML, Roldan V, Bellosillo B, García-Barberá N, Rivera J, et al. JAK2 V617F, hemostatic polymorphisms, and clinical features as risk factors for arterial thrombotic events in essential thrombocythemia. Ann Hematol. 2008;87:763–5.PubMedCrossRef

34.

Arellano-Rodrigo E, Alvarez-Larran A, Reverter JC, Colomer D, Villamor N, Bellosillo B, et al. Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden. Am J Hematol. 2009;84:102–8.PubMedCrossRef

35.

Patriarca A, Pompetti F, Malizia R, Iuliani O, Di Marzio I, Spadano A, et al. Is the absence of JAK2 mutation a risk factor for bleeding in essential thrombocythemia? An analysis of 106 patients. Blood Transfus. 2010;8:21–7.PubMedCentralPubMed

36.

De Stefano V, Rossi E, Za T, Ciminello A, Betti S, Luzzi C, et al. JAK2 V617F mutational frequency in essential thrombocythemia associated with splanchnic or cerebral vein thrombosis. Am J Hematol. 2011;86:526–8.PubMedCrossRef

37.

Pich A, Riera L, Beggiato E, Nicolino B, Godio L, Campisi P, et al. JAK2V617F mutation and allele burden are associated with distinct clinical and morphological subtypes in patients with essential thrombocythaemia. J Clin Pathol. 2012;65:953–5.PubMedCrossRef

38.

Coucelo M, Caetano G, Sevivas T, Almeida Santos S, Fidalgo T, Bento C, et al. JAK2V617F allele burden is associated with thrombotic mechanisms activation in polycythemia vera and essential thrombocythemia patients. Int J Hematol. 2014;99:32–40.PubMedCrossRef

39.

Ohyashiki K, Ito Y, Hori K, Sato K, Makino T, Ohyashiki JH. Thrombosis can occur at any phase of essential thrombocythemia with JAK2(V617F) mutation: a single institutional study in Japan. Leukemia. 2007;21:1570–1.PubMedCrossRef

40.

Wong RS, Cheng CK, Chan NP, Cheng SH, Wong WS, Lau KM, et al. JAK2 V617F mutation is associated with increased risk of thrombosis in Chinese patients with essential thrombocythaemia. Br J Haematol. 2008;141:902–4.PubMedCrossRef

41.

Cho YU, Chi HS, Lee EH, Jang S, Park CJ, Seo EJ. Comparison of clinicopathologic findings according to JAK2 V617F mutation in patients with essential thrombocythemia. Int J Hematol. 2009;89:39–44.PubMedCrossRef

42.

Chim CS, Sim JP, Chan CC, Kho BC, Chan JC, Wong LG, et al. Impact of JAK2V617F mutation on thrombosis and myeloid transformation in essential thrombocythemia: a multivariate analysis by Cox regression in 141 patients. Hematology. 2010;15:187–92.PubMedCrossRef

43.

Takata Y, Seki R, Kanajii T, Nohara M, Koteda S, Kawaguchi K, et al. Association between thromboembolic events and the JAK2 V617F mutation in myeloproliferative neoplasms. Kurume Med J. 2014;60:89–97.PubMedCrossRef

44.

Heller PG, Lev PR, Salim JP, Goette NP, Chazarreta CD, Glembotsky AC, et al. JAK2V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphorylation status. Eur J Haematol. 2006;77:210–6.PubMedCrossRef

45.

Pemmaraju N, Moliterno AR, Williams DM, Rogers O, Spivak JL. The quantitative JAK2 V617F neutrophil allele burden does not correlate with thrombotic risk in essential thrombocytosis. Leukemia. 2007;21:2210–2.PubMedCrossRef

46.

Basquiera AL, Soria NW, Ryser R, Salguero M, Moiraghi B, Sackmann F, et al. Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders. Hematology. 2009;14:323–30.PubMedCrossRef

47.

Gangat N, Wassie E, Lasho T, Finke C, Ketterling RP, Hanson CA, et al. Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history. Eur J Haematol. 2015;94(1):31–6.PubMedCrossRef

48.

Stevenson WS, Hoyt R, Bell A, Guipponi M, Juneja S, Grigg AP, et al. Genetic heterogeneity of granulocytes for the JAK2 V617F mutation in essential thrombocythaemia: implications for mutation detection in peripheral blood. Pathology. 2006;38:336–42.PubMedCrossRef

49.

Weston H, Cowell V, Grimmett K, Saal R, Jones M, Mills T, et al. Prognostic utility of spontaneous erythroid colony formation and JAK2 mutational analysis for thrombotic events in essential thrombocythaemia. Intern Med J. 2011;41:408–15.PubMedCrossRef

50.

Tefferi A, Wassie EA, Lasho TL, Finke C, Belachew AA, Ketterling RP, et al. Calreticulin mutations and long-term survival in essential thrombocythemia. Leukemia. 2014;28:2300–3.PubMedCrossRef

51.

Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood. 2011;117:5857–9.PubMedCrossRef

52.

Montanaro M, Latagliata R, Cedrone M, Spadea A, Rago A, Di Giandomenico J, et al. Thrombosis and survival in essential thrombocythemia: a regional study of 1,144 patients. Am J Hematol. 2014;89:542–6.PubMedCrossRef

53.

Casini A, Fontana P, Lecompte TP. Thrombotic complications of myeloproliferative neoplasms: risk assessment and risk-guided management. J Thromb Haemost. 2013;11:1215–27.PubMedCrossRef

54.

Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120:5128–33.PubMedCrossRef

55.

Carobbio A, Antonioli E, Guglielmelli P, Vannucchi AM, Delaini F, Guerini V, et al. Leukocytosis and risk stratification assessment in essential thrombocythemia. J Clin Oncol. 2008;26(16):2732–6.PubMedCrossRef

56.

Cheng YJ, Liu ZH, Yao FJ, Zeng WT, Zheng DD, Dong YG, et al. Current and former smoking and risk for venous thromboembolism: a systematic review and meta-analysis. PLoS Med. 2013;10(9):e1001515.PubMedCentralPubMedCrossRef

57.

Vaya A, Suescun M. Hemorheological parameters as independent predictors of venous thromboembolism. Clin Hemorheol Microcirc. 2013;53(1–2):131–41.PubMed

58.

Yang Y, Wang X, Wang C, Qin Y. A meta-analysis comparing clinical characteristics and outcomes in CALR-mutated and JAK2V617F essential thrombocythaemia. Int J Hematol. 2015;101(2):165–72.PubMedCrossRef

Titel: The impact of JAK2V617F mutation on different types of thrombosis risk in patients with essential thrombocythemia: a meta-analysis
verfasst von: Youwen Qin
Xiaorui Wang
Chuxian Zhao
Chun Wang
Yining Yang
Publikationsdatum: 01.08.2015
Verlag: Springer Japan
Erschienen in: International Journal of Hematology / Ausgabe 2/2015
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-015-1808-y

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

The impact of JAK2V617F mutation on different types of thrombosis risk in patients with essential thrombocythemia: a meta-analysis

Abstract

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2015

Successful treatment of refractory cold hemagglutinemia in MYD88 L265P mutation-negative Waldenström’s macroglobulinemia with bortezomib

High-dose methotrexate, etoposide, dexamethasone and pegaspargase (MEDA) combination chemotherapy is effective for advanced and relapsed/refractory extranodal natural killer/T cell lymphoma: a retrospective study

Prognostic impact of residual normal metaphases in acute myeloid leukemia with t(8;21)(q22;q22)

Successful treatment of adult Langerhans cell histiocytosis with intensified chemotherapy

Decrease of B-type natriuretic peptide to less than 200 pg/mL predicts longer survival in cardiac immunoglobulin light chain amyloidosis

Outcome of a novel immunosuppressive strategy of cyclosporine, levamisole and danazol for severe aplastic anemia

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie